Protez Pharmaceuticals, Inc.

V-073, an enterovirus capsid inhibitor, was evaluated for its spectrum of antipoliovirus activity. V-073 inhibited all 45 polioviruses tested in a virus-induced cytopathic effect protection assay, with 50% effective concentration (EC 50 ) values ranging from 0.003 to 0.126 μM. Ninety percent of the polioviruses tested were inhibited at EC 50 s of ≤0.076 μM (MIC 90 = 32 ng/ml). V-073 is a promising antiviral candidate for the posteradication management of poliovirus incidents.